Evogene Ltd. current report, Q1 FY2024

Business Context and Reporting Period

This Form 6-K filing by Evogene Ltd. covers the month of March 2024, with the report dated March 28, 2024. The filing primarily announces a new equity financing arrangement and the termination of a prior agreement.

Key Financial Metrics and Capital Structure

The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the period. Instead, it details specific capital raising activities:

  • New ATM Offering: Entered into a Sales Agreement with Lake Street Capital Markets, LLC to sell ordinary shares with an aggregate offering price of up to $7.3 million.
  • Commission: The Company will pay a cash commission of 3.0% of gross proceeds to the Agent.
  • Prior Proceeds: Under the terminated Cantor Fitzgerald agreement, the Company received approximately $3,261,000 in net proceeds prior to termination.
  • Debt and Liquidity: The filing text does not provide clear values for current debt levels, cash balances, or liquidity ratios.

Material Changes Versus Prior Period

The primary material change is the replacement of the Company's equity distribution mechanism:

  • Termination of Cantor Agreement: The Controlled Equity Offering Agreement with Cantor Fitzgerald & Co., originally dated February 19, 2021, was terminated effective March 27, 2024. The original agreement allowed for sales up to $19,449,865.
  • Initiation of Lake Street Agreement: Concurrently, the Company initiated a new "at the market" (ATM) offering with Lake Street Capital Markets, LLC, capping potential sales at $7.3 million.
  • Cost Implications: No termination penalties were incurred regarding the Cantor Agreement.

Guidance, Outlook, and Risks

Management Commentary and Outlook: The Company is not obligated to sell any shares under the new Sales Agreement. There is no assurance regarding the price, number of shares, or timing of any future sales. The Agent will sell shares based on the Company's instructions, including price and size limits.

Risks and Contingencies:

  • Market Risk: Sales are subject to market conditions and the Company's discretion to impose parameters.
  • Termination Risk: The Sales Agreement may be terminated by either party as set forth in the agreement terms.
  • Regulatory Compliance: The filing notes that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration.

Important Facts for Investor Verification

  • Verify the current cash position and burn rate to assess the necessity of the new $7.3 million ATM facility.
  • Confirm the exact number of shares authorized for issuance under the new Lake Street agreement versus the remaining capacity of the terminated Cantor agreement.
  • Review the Company's recent stock price volatility to gauge the potential dilution impact of the 3.0% commission and future share sales.
  • Check subsequent filings to determine if any shares have actually been sold under the new Lake Street agreement since March 28, 2024.